161
Participants
Start Date
April 30, 2013
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
High Hb target
"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
cholecalciferol
1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
CANDLE Trial Study Group, Suita
Collaborators (1)
Chugai Pharmaceutical
INDUSTRY
Japanese Society for the Promotion of Science
OTHER
The Japan Kidney Foundation
OTHER
Roche Diagnostics GmbH
INDUSTRY
CANDLE-KIT Trial Study Group
OTHER